Head-To-Head Contrast: Brainstorm Cell Therapeutics (NASDAQ:BCLI) vs. Protara Therapeutics (NASDAQ:TARA)

Protara Therapeutics (NASDAQ:TARA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Risk & Volatility

Protara Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Institutional and Insider Ownership

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 12.5% of Protara Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Protara Therapeutics and Brainstorm Cell Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$40.42 million	($2.40)	-1.84
Brainstorm Cell Therapeutics	N/A	N/A	-$17.19 million	($4.80)	-0.33

Protara Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Protara Therapeutics and Brainstorm Cell Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	0	0	5	0	3.00
Brainstorm Cell Therapeutics	0	0	1	0	3.00

Protara Therapeutics presently has a consensus target price of $22.50, suggesting a potential upside of 409.05%. Brainstorm Cell Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 1,798.73%. Given Brainstorm Cell Therapeutics’ higher possible upside, analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Protara Therapeutics.

Profitability

This table compares Protara Therapeutics and Brainstorm Cell Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-55.96%	-49.06%
Brainstorm Cell Therapeutics	N/A	N/A	-528.56%

Summary

Protara Therapeutics beats Brainstorm Cell Therapeutics on 6 of the 10 factors compared between the two stocks.

About Protara Therapeutics

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.